Altium Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Altium Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-49,333	Closed	-$185K	–	7
2025 Q1	$185K	Hold	49,333	–	–	0.44%	20
2024 Q4	$500K	Hold	49,333	–	–	0.14%	59
2024 Q3	$614K	Hold	49,333	–	–	0.18%	53
2024 Q2	$642K	Hold	49,333	–	–	0.26%	37
2024 Q1	$1.12M	Hold	49,333	–	–	0.44%	41
2023 Q4	$640K	Hold	49,333	–	–	0.43%	34
2023 Q3	$992K	Hold	49,333	–	–	0.52%	39
2023 Q2	$1.32M	Buy	49,333 +15,614	+46%	+$672K	1%	26
2023 Q1	$1.97M	Buy	+33,719	New	+$1.66M	1.09%	35
2022 Q4	–	Sell	-50,000	Closed	-$4.09M	–	115
2022 Q3	$4.09M	Buy	50,000 +3,333	+7%	+$249K	1.5%	20
2022 Q2	$3.16M	Buy	46,667 +3,667	+9%	+$336K	1.26%	30
2022 Q1	$4.75M	Buy	+43,000	New	+$5.36M	1.59%	22
2021 Q1	–	Sell	-8,930	Closed	-$2.07M	–	134
2020 Q4	$2.07M	Buy	+8,930	New	+$2.07M	0.77%	56

Other funds holding KPTI

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Altium Capital Management's KPTI Position: Q2 2025 in Review

Altium Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2025, closing a stake of 49,333 shares — an estimated $185K sold.

Altium Capital Management first reported a position in KPTI in Q4 2020 and held it in 13 quarters. The position peaked at $4.75M in Q1 2022. 50 funds tracked by Wall St. Rank hold KPTI as of Q2 2025.

Altium Capital Management reported no remaining Karyopharm Therapeutics position as of Q2 2025 after selling out during the quarter.
Altium Capital Management sold 49,333 Karyopharm Therapeutics shares in Q2 2025, an estimated $185K.
Altium Capital Management first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 13 quarters.
Altium Capital Management's Karyopharm Therapeutics position peaked at $4.75M in Q1 2022.
50 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.